Wedbush Analysts Boost Earnings Estimates for BDTX

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Stock analysts at Wedbush upped their Q1 2025 earnings per share estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now anticipates that the company will earn $0.92 per share for the quarter, up from their prior estimate of ($0.28). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ FY2025 earnings at $0.07 EPS.

A number of other brokerages have also recently commented on BDTX. Stifel Nicolaus dropped their target price on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 7th. HC Wainwright lifted their price objective on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $14.60.

Black Diamond Therapeutics Trading Down 5.6 %

BDTX opened at $1.68 on Monday. The stock has a 50-day moving average of $2.15 and a 200 day moving average of $2.82. Black Diamond Therapeutics has a 12 month low of $1.59 and a 12 month high of $7.66. The firm has a market cap of $95.19 million, a P/E ratio of -1.26 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03.

Insider Transactions at Black Diamond Therapeutics

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total value of $11,973,484.44. Following the transaction, the insider now directly owns 2,733,547 shares in the company, valued at approximately $5,658,442.29. This represents a 67.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 8.87% of the company’s stock.

Institutional Trading of Black Diamond Therapeutics

A number of large investors have recently modified their holdings of BDTX. D. E. Shaw & Co. Inc. purchased a new position in Black Diamond Therapeutics during the 4th quarter valued at about $37,000. Intech Investment Management LLC increased its holdings in Black Diamond Therapeutics by 49.1% during the fourth quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock valued at $41,000 after buying an additional 6,340 shares during the period. JPMorgan Chase & Co. raised its stake in Black Diamond Therapeutics by 429.6% in the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after buying an additional 15,355 shares in the last quarter. SG Americas Securities LLC bought a new position in Black Diamond Therapeutics in the fourth quarter worth approximately $42,000. Finally, Wells Fargo & Company MN lifted its holdings in Black Diamond Therapeutics by 41.8% during the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after buying an additional 5,932 shares during the period. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.